Eliquis (apixaban) available at more than 40 per cent discount; Sotyktu to be offered at more than 80 per cent discount to current list price
Expanded capabilities that continue to push the boundaries of innovation—advancing drug delivery solutions for patients, customers, and consumers around the world
BIL also holds an option to increase its equity stake by an additional 15%
_LOGO_256_384.jpg){kind=logo}
The association called for an end to the constant issuance of regulatory circulars that make operations unpredictable and capital-intensive.
Alkem's Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab
Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
Launches National IVD validation portal and protocols; highlights India’s strengthening health research ecosystem
Advent acquired Zentiva from Sanofi in 2018 and transformed the company into a highly successful standalone business
Subscribe To Our Newsletter & Stay Updated
